The Regulatory Affairs Professionals Society (RAPS) is an international membership organization of regulatory professionals in the healthcare products sector.
Brand-name and generic pharmaceutical groups are recommending clarifications to the FDA guidance on when to submit an abbreviated new drug application or a 505(b)(2) new drug application.
https://t.co/1XRW4eODMu
The FDA is requesting feedback on possible solutions that would help sponsors more effectively submit patient-level real-world data and real-world evidence for drug and biological product applications.
https://t.co/uo18OfBujp
Acting US FDA Commissioner Kyle Diamantas said there is significant public interest in its recently announced Expedited Investigational New Drug pilot at the Friends of Cancer Research annual meeting on Tuesday.
https://t.co/yFLfQSACi2
The FDA has issued draft guidance to assist sponsors in developing early-phase first-in-human studies for investigational drugs and biologics aimed at treating solid tumors as part of Operation TrialBlazer.
https://t.co/GxT2IdtXU8
FDA on Monday finalized guidance to assist manufacturers in validating in vitro diagnostic devices that test for emerging pathogens during public health emergencies.
https://t.co/mtj6d45764
A FDA official stated that the midterm congressional election results will not likely impact the reauthorization of the agency’s user fee agreements, which have been negotiated for FY 2028-2032.
https://t.co/WVN0InEs2A
As artificial intelligence (AI) permeates the regulatory world, experts said it won't take over regulatory professionals' jobs but will instead help them work more efficiently and dedicate more time on human interactions.
https://t.co/bhpsRz8lRV
Sarah Yim, director of the FDA Office of Therapeutic Biologics and Biosimilars in the Office of New Drugs, emphasized that the agency is actively working to help sponsors reduce their reliance on clinical efficacy studies.
https://t.co/6diNbeGXmM
A top US FDA enforcement official announced that the agency conducted more unannounced drug inspections in India and China in FY 2026 compared to the previous year.
https://t.co/LiMOqUytXv
More than 500 comments have been submitted in response to the FDA discussion paper on generative AI (genAI)-enabled medical devices, and stakeholders have offered the agency a wide variety of advice on the best way to regulate these technologies.
https://t.co/H7ePekeytJ
Patients who reviewed and signed a patient agreement form (PAF) for mifepristone and misoprostol under the FDA risk evaluation and mitigation strategy program were equally knowledgeable about medication abortion.
https://t.co/L7M7IKnQPz
FDA issued revised draft guidance on Thursday aimed at assisting sponsors of drug-device combination products in designing and developing essential drug delivery device performance characteristics for their products.
https://t.co/V2A8LNWmoc
The Department of Health and Human Services has announced that it will not take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound six unapproved peptide bulk drug substances.
https://t.co/pTSKunLh8f
FDA on Tuesday issued draft guidance on submitting investigational device exemption applications electronically using the electronic Submission Template and Resource template.
Joanne Eglovitch reports for Regulatory Focus: https://t.co/PS2MiP9dSr
An expert and officials from FDA offered tips for de novo classification requests and reviewed some of the changes related to de novos being proposed under the Medical Device User Fee Amendments (MDUFA VI) program at The MedTech Conference last week.
https://t.co/zwTsYvUZa1
FDA on Tuesday issued draft guidance laying out its proposed regulatory approach to overseeing individualized gene editing products, including those that feature multiple product variants developed under a single investigational new drug application.
https://t.co/PCVcr5WxQp
Acting US FDA Commissioner Kyle Diamantas touted the agency’s new rare disease framework as the best mechanism for modernizing rare disease development and incorporating the patient voice into scientific reviews for orphan therapies.
https://t.co/oG8uwCQrLW
There needs to be a cultural shift to foster trust between regulators and the medtech industry when developing real-world evidence to support the marketing of medical devices, according to experts who spoke at The MedTech Conference on Monday.
https://t.co/SYf7cPGGxF
Major pharmaceutical companies are urging the FDA to adopt a more flexible, risk-based approach in its guidance on testing container-closure systems for drugs and biological products, especially when established materials and technologies are used.
https://t.co/BKPeaFUo6o